Combination therapy with saluretics and atenolol in essential hypertension. Effects on blood pressure, electrolytes and uric acid.
D000319:Adrenergic beta-Antagonists; D000328:Adult; D000368:Aged; D001262:Atenolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001539:Bendroflumethiazide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002752:Chlorthalidone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004573:Electrolytes / Q000097:blood*; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008529:Mefruside / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood*
D000319:Adrenergic beta-Antagonists; D004232:Diuretics; D004573:Electrolytes; D011412:Propanolamines; D006852:Hydrochlorothiazide; D014527:Uric Acid; D001262:Atenolol; D001539:Bendroflumethiazide; D002752:Chlorthalidone; D008529:Mefruside